The combined therapy of abemaciclib and olaparib synergistically suppressed tumor growth in the xenograft model, and samples derived from animal tumors were used to confirm the key role of PARP1 in CDK4/6i resistance by immunohistochemical assay (Fig. 6A–C, G). The gene discussed is PARP1; the disease is neoplasm.